Zynex Inc (ZYXI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zynex Inc (ZYXI) has a cash flow conversion efficiency ratio of 0.152x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.31 Million) by net assets ($-41.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zynex Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Zynex Inc - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Zynex Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zynex Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zynex Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dongbu Corp
KO:005965
|
0.058x |
|
CDN Maverick Capital Corp.
F:338B
|
-0.120x |
|
Vendetta Mining Corp
V:VTT
|
-0.002x |
|
GeoVax Labs Inc
NASDAQ:GOVX
|
-1.266x |
|
Aminex PLC
STU:DOP
|
-0.014x |
|
ZW Data Action Technologies Inc
NASDAQ:CNET
|
-0.067x |
|
Awilco Drilling PLC
OL:AWDR
|
0.616x |
|
Chimeric Therapeutics Ltd
AU:CHM
|
1.268x |
Annual Cash Flow Conversion Efficiency for Zynex Inc (2000–2024)
The table below shows the annual cash flow conversion efficiency of Zynex Inc from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see Zynex Inc (ZYXI) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $35.71 Million | $12.72 Million | 0.356x | -7.45% |
| 2023-12-31 | $46.13 Million | $17.76 Million | 0.385x | +85.82% |
| 2022-12-31 | $66.36 Million | $13.75 Million | 0.207x | +120.37% |
| 2021-12-31 | $73.92 Million | $6.95 Million | 0.094x | +553.35% |
| 2020-12-31 | $56.85 Million | $818.00K | 0.014x | -95.51% |
| 2019-12-31 | $19.65 Million | $6.30 Million | 0.321x | -68.30% |
| 2018-12-31 | $9.30 Million | $9.41 Million | 1.012x | -39.95% |
| 2017-12-31 | $4.90 Million | $8.26 Million | 1.685x | +476.85% |
| 2016-12-31 | $-3.80 Million | $1.70 Million | -0.447x | -433.81% |
| 2015-12-31 | $-4.07 Million | $341.00K | -0.084x | +88.96% |
| 2014-12-31 | $-1.27 Million | $961.00K | -0.758x | -862.60% |
| 2013-12-31 | $4.85 Million | $-382.00K | -0.079x | -8.06% |
| 2012-12-31 | $12.05 Million | $-879.00K | -0.073x | -104.24% |
| 2011-12-31 | $10.14 Million | $-362.00K | -0.036x | +56.08% |
| 2010-12-31 | $8.18 Million | $-665.00K | -0.081x | -116.68% |
| 2009-12-31 | $7.49 Million | $3.65 Million | 0.487x | +425.29% |
| 2008-12-31 | $4.77 Million | $-715.16K | -0.150x | -172.56% |
| 2007-12-31 | $3.62 Million | $746.86K | 0.206x | +154.98% |
| 2006-12-31 | $1.29 Million | $-483.46K | -0.376x | +23.75% |
| 2005-12-31 | $440.77K | $-217.06K | -0.492x | +90.58% |
| 2004-12-31 | $202.89K | $-1.06 Million | -5.229x | -25607.87% |
| 2003-12-31 | $-461.11K | $-9.45K | 0.021x | -98.71% |
| 2000-12-31 | $-594.94K | $-945.18K | 1.589x | -- |
About Zynex Inc
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) dev… Read more